Retinopathy of prematurity: Controversies in the usage of intraocular antiangiogenics

Marco A. Ramírez-Ortiz, Citlali Lara-Molina, Dina Villanueva-García, Mónica Villa-Guillén, Luis Jasso-Gutiérrez, Leyla Carolina Padilla-Sierra, Violeta Robredo-Torres, Juan Carlos Bravo-Ortiz, José Alfonso Gutiérrez Padilla, Eusebio Angulo Castellanos, Javier Mancilla Ramírez, Manuel Bernardo Salgado-Valladares, María Graciela Hernández-Peláez, Leonor Hernández Salazar, Luis Porfirio Orozco Gómez, Luz Consuelo Zepeda-Romero

Research output: Contribution to journalArticle

Abstract

The increase in survival rates among preterm infants, characteristics of neonatal care for such infants and a lack of suitable programs for preventing, detecting and treating retinopathy of prematurity (ROP) are factors that have made this disease the main cause of preventable blindness among children in Mexico. The advent of antiangiogenic agents in cancer treatment and their off-label use with favorable results in the treatment of proliferative vessel disease of the retina among adult patients, as well as anecdotal reports in the literature and a series of cases showing serious methodological flaws, have prompted their use in the treatment of retinopathy of prematurity. Unfortunately, these agents used indiscriminately in our country have a systemic absorption and secondary effects on the preterm patient's body. There are no long-term monitoring studies that guarantee their safe use in this segment of the population. This article describes the situation in our country and warns of the risks posed by the use of this type of drug on the preterm infant population.
Original languageAmerican English
Pages (from-to)344-350
Number of pages308
JournalBoletin Medico del Hospital Infantil de Mexico
StatePublished - 1 Sep 2013
Externally publishedYes

Fingerprint

Retinopathy of Prematurity
Premature Infants
Angiogenesis Inhibitors
Oncology
blindness
Off-Label Use
Infant Care
Labels
retina
Mexico
Blindness
Defects
Population
vessels
Retina
Monitoring
drugs
Therapeutics
Survival Rate
cancer

Cite this

Ramírez-Ortiz, M. A., Lara-Molina, C., Villanueva-García, D., Villa-Guillén, M., Jasso-Gutiérrez, L., Padilla-Sierra, L. C., ... Zepeda-Romero, L. C. (2013). Retinopathy of prematurity: Controversies in the usage of intraocular antiangiogenics. Boletin Medico del Hospital Infantil de Mexico, 344-350.
Ramírez-Ortiz, Marco A. ; Lara-Molina, Citlali ; Villanueva-García, Dina ; Villa-Guillén, Mónica ; Jasso-Gutiérrez, Luis ; Padilla-Sierra, Leyla Carolina ; Robredo-Torres, Violeta ; Bravo-Ortiz, Juan Carlos ; Padilla, José Alfonso Gutiérrez ; Castellanos, Eusebio Angulo ; Ramírez, Javier Mancilla ; Salgado-Valladares, Manuel Bernardo ; Hernández-Peláez, María Graciela ; Salazar, Leonor Hernández ; Gómez, Luis Porfirio Orozco ; Zepeda-Romero, Luz Consuelo. / Retinopathy of prematurity: Controversies in the usage of intraocular antiangiogenics. In: Boletin Medico del Hospital Infantil de Mexico. 2013 ; pp. 344-350.
@article{6b276b477b06447e8d095a8af4533840,
title = "Retinopathy of prematurity: Controversies in the usage of intraocular antiangiogenics",
abstract = "The increase in survival rates among preterm infants, characteristics of neonatal care for such infants and a lack of suitable programs for preventing, detecting and treating retinopathy of prematurity (ROP) are factors that have made this disease the main cause of preventable blindness among children in Mexico. The advent of antiangiogenic agents in cancer treatment and their off-label use with favorable results in the treatment of proliferative vessel disease of the retina among adult patients, as well as anecdotal reports in the literature and a series of cases showing serious methodological flaws, have prompted their use in the treatment of retinopathy of prematurity. Unfortunately, these agents used indiscriminately in our country have a systemic absorption and secondary effects on the preterm patient's body. There are no long-term monitoring studies that guarantee their safe use in this segment of the population. This article describes the situation in our country and warns of the risks posed by the use of this type of drug on the preterm infant population.",
author = "Ram{\'i}rez-Ortiz, {Marco A.} and Citlali Lara-Molina and Dina Villanueva-Garc{\'i}a and M{\'o}nica Villa-Guill{\'e}n and Luis Jasso-Guti{\'e}rrez and Padilla-Sierra, {Leyla Carolina} and Violeta Robredo-Torres and Bravo-Ortiz, {Juan Carlos} and Padilla, {Jos{\'e} Alfonso Guti{\'e}rrez} and Castellanos, {Eusebio Angulo} and Ram{\'i}rez, {Javier Mancilla} and Salgado-Valladares, {Manuel Bernardo} and Hern{\'a}ndez-Pel{\'a}ez, {Mar{\'i}a Graciela} and Salazar, {Leonor Hern{\'a}ndez} and G{\'o}mez, {Luis Porfirio Orozco} and Zepeda-Romero, {Luz Consuelo}",
year = "2013",
month = "9",
day = "1",
language = "American English",
pages = "344--350",
journal = "Boletin Medico del Hospital Infantil de Mexico",
issn = "1665-1146",
publisher = "Hospital Infantil de Mexico Federico Gomez",

}

Ramírez-Ortiz, MA, Lara-Molina, C, Villanueva-García, D, Villa-Guillén, M, Jasso-Gutiérrez, L, Padilla-Sierra, LC, Robredo-Torres, V, Bravo-Ortiz, JC, Padilla, JAG, Castellanos, EA, Ramírez, JM, Salgado-Valladares, MB, Hernández-Peláez, MG, Salazar, LH, Gómez, LPO & Zepeda-Romero, LC 2013, 'Retinopathy of prematurity: Controversies in the usage of intraocular antiangiogenics', Boletin Medico del Hospital Infantil de Mexico, pp. 344-350.

Retinopathy of prematurity: Controversies in the usage of intraocular antiangiogenics. / Ramírez-Ortiz, Marco A.; Lara-Molina, Citlali; Villanueva-García, Dina; Villa-Guillén, Mónica; Jasso-Gutiérrez, Luis; Padilla-Sierra, Leyla Carolina; Robredo-Torres, Violeta; Bravo-Ortiz, Juan Carlos; Padilla, José Alfonso Gutiérrez; Castellanos, Eusebio Angulo; Ramírez, Javier Mancilla; Salgado-Valladares, Manuel Bernardo; Hernández-Peláez, María Graciela; Salazar, Leonor Hernández; Gómez, Luis Porfirio Orozco; Zepeda-Romero, Luz Consuelo.

In: Boletin Medico del Hospital Infantil de Mexico, 01.09.2013, p. 344-350.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Retinopathy of prematurity: Controversies in the usage of intraocular antiangiogenics

AU - Ramírez-Ortiz, Marco A.

AU - Lara-Molina, Citlali

AU - Villanueva-García, Dina

AU - Villa-Guillén, Mónica

AU - Jasso-Gutiérrez, Luis

AU - Padilla-Sierra, Leyla Carolina

AU - Robredo-Torres, Violeta

AU - Bravo-Ortiz, Juan Carlos

AU - Padilla, José Alfonso Gutiérrez

AU - Castellanos, Eusebio Angulo

AU - Ramírez, Javier Mancilla

AU - Salgado-Valladares, Manuel Bernardo

AU - Hernández-Peláez, María Graciela

AU - Salazar, Leonor Hernández

AU - Gómez, Luis Porfirio Orozco

AU - Zepeda-Romero, Luz Consuelo

PY - 2013/9/1

Y1 - 2013/9/1

N2 - The increase in survival rates among preterm infants, characteristics of neonatal care for such infants and a lack of suitable programs for preventing, detecting and treating retinopathy of prematurity (ROP) are factors that have made this disease the main cause of preventable blindness among children in Mexico. The advent of antiangiogenic agents in cancer treatment and their off-label use with favorable results in the treatment of proliferative vessel disease of the retina among adult patients, as well as anecdotal reports in the literature and a series of cases showing serious methodological flaws, have prompted their use in the treatment of retinopathy of prematurity. Unfortunately, these agents used indiscriminately in our country have a systemic absorption and secondary effects on the preterm patient's body. There are no long-term monitoring studies that guarantee their safe use in this segment of the population. This article describes the situation in our country and warns of the risks posed by the use of this type of drug on the preterm infant population.

AB - The increase in survival rates among preterm infants, characteristics of neonatal care for such infants and a lack of suitable programs for preventing, detecting and treating retinopathy of prematurity (ROP) are factors that have made this disease the main cause of preventable blindness among children in Mexico. The advent of antiangiogenic agents in cancer treatment and their off-label use with favorable results in the treatment of proliferative vessel disease of the retina among adult patients, as well as anecdotal reports in the literature and a series of cases showing serious methodological flaws, have prompted their use in the treatment of retinopathy of prematurity. Unfortunately, these agents used indiscriminately in our country have a systemic absorption and secondary effects on the preterm patient's body. There are no long-term monitoring studies that guarantee their safe use in this segment of the population. This article describes the situation in our country and warns of the risks posed by the use of this type of drug on the preterm infant population.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84886046464&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84886046464&origin=inward

M3 - Article

SP - 344

EP - 350

JO - Boletin Medico del Hospital Infantil de Mexico

JF - Boletin Medico del Hospital Infantil de Mexico

SN - 1665-1146

ER -

Ramírez-Ortiz MA, Lara-Molina C, Villanueva-García D, Villa-Guillén M, Jasso-Gutiérrez L, Padilla-Sierra LC et al. Retinopathy of prematurity: Controversies in the usage of intraocular antiangiogenics. Boletin Medico del Hospital Infantil de Mexico. 2013 Sep 1;344-350.